PHAR
Pharming Group NV
NASDAQ: PHAR · HEALTHCARE · BIOTECHNOLOGY
$16.53
+1.07% today
Updated 2026-04-30
Market cap
$1.16B
P/E ratio
408.88
P/S ratio
3.07x
EPS (TTM)
$0.04
Dividend yield
—
52W range
$9 – $21
Volume
0.0M
Pharming Group NV (PHAR) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.76%
Operating margin
2.84%
ROE
1.02%
ROA
4.55%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | $194010.00 | $-24.41M | 100.00% | -12,267.39% | -12,582.36% |
| 2007 | $1.01M | $-51.92M | -3,568.26% | -3,568.26% | -5,161.16% |
| 2008 | $924353.00 | $-36.48M | 100.00% | -4,437.80% | -3,946.54% |
| 2009 | $1.57M | $-45.93M | 100.00% | -2,540.88% | -2,925.18% |
| 2010 | $762069.00 | $-74.97M | 84.12% | -7,701.75% | -9,837.18% |
| 2011 | $3.89M | $-22.17M | -17.71% | -616.91% | -570.32% |
| 2012 | $14.04M | $-31.86M | 59.79% | -164.52% | -227.01% |
| 2013 | $9.45M | $-20.80M | 83.75% | -100.99% | -220.05% |
| 2014 | $25.76M | $-7.01M | 83.82% | 13.58% | -27.22% |
| 2015 | $11.84M | $-10.89M | 55.67% | -118.53% | -91.96% |
| 2016 | $16.69M | $-18.44M | 70.50% | -72.70% | -110.48% |
| 2017 | $107.52M | $-95.92M | 86.11% | 24.45% | -89.22% |
| 2018 | $154.58M | $28.59M | 83.59% | 28.12% | 18.50% |
| 2019 | $189.39M | $40.56M | 87.37% | 36.03% | 21.41% |
| 2020 | $212.17M | $37.75M | 88.91% | 35.94% | 17.79% |
| 2021 | $198.87M | $16.00M | 89.37% | 6.82% | 8.04% |
| 2022 | $205.62M | $13.67M | 91.46% | 8.87% | 6.65% |
| 2023 | $245.32M | $-10.55M | 89.72% | -2.20% | -4.30% |
| 2024 | $297.20M | $-11.84M | 88.09% | -2.90% | -3.98% |
| 2025 | $377.18M | $2.86M | 87.90% | 5.13% | 0.76% |